The role of itaconate in host defense and inflammation.

Peace CG, O'Neill LA. · 2022

Read The role of itaconate in host defense and inflammation. by Peace CG, O'Neill LA. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8759771.txt.

Introduction

Peace and O'Neill review itaconate, a metabolite that has emerged as a key player in host defense and inflammation. When macrophages meet inflammatory triggers, they rewire their metabolism. Breaks in the Krebs cycle let certain metabolites pile up. Itaconate is one of those, made by an enzyme switched on during inflammation.

Itaconate blocks a key energy enzyme and curbs sugar breakdown. It switches on anti-inflammatory gene programs in the cell. It also blocks a major inflammatory complex called the inflammasome. In animal models, it and its derivatives calmed sepsis, viral infection, and skin disease. The review maps a metabolite turned immune signal.

Catalog record

CREATORPeace CG, O'Neill LA.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE63 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8759771

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The role of itaconate in host defense and inflammation By Christian G Peace, Luke AJ O’Neill Published in: The Journal of Clinical Investigation DOI: 10.1172/JCI148548 ABSTRACT Abstract Macrophages exposed to inflammatory stimuli including LPS undergo metabolic reprogramming to facilitate macrophage effector function. This metabolic reprogramming supports phagocytic function, cytokine release, and ROS production that are critical to protective inflammatory responses. The Krebs cycle is a central metabolic pathway within all mammalian cell types. In activated macrophages, distinct breaks in the Krebs cycle regulate macrophage effector function through the accumulation of several metabolites that were recently shown to have signaling roles in immunity. One metabolite that accumulates in macrophages because of the disturbance in the Krebs cycle is itaconate, which is derived from cis-aconitate by the enzyme cis-aconitate decarboxylase (ACOD1), encoded by immunoresponsive gene 1 (Irg1). This Review focuses on itaconate’s emergence as a key immunometabolite with diverse roles in immunity and inflammation. These roles include inhibition of succinate dehydrogenase (which controls levels of succinate, a metabolite with multiple roles in inflammation), inhibition of glycolysis at multiple levels (which will limit inflammation), activation of the antiinflammatory transcription factors Nrf2 and ATF3, and inhibition of the NLRP3 inflammasome. Itaconate and its derivatives have antiinflammatory effects in preclinical models of sepsis, viral infections, psoriasis, gout, ischemia/reperfusion injury, and pulmonary fibrosis, pointing to possible itaconate-based therapeutics for a range of inflammatory diseases. This intriguing metabolite continues to yield fascinating insights into the role of metabolic reprogramming in host defense and inflammation. Macrophages, upon classical activation by the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS), undergo metabolic reprogramming to meet newly required bioenergetic and biosynthetic demands that regulate macrophage effector function. Generally, anabolic pathways that fuel biosynthesis, such as aerobic glycolysis (termed the “Warburg effect”), are highly upregulated, whereas catabolic pathways such as oxidative phosphorylation (OXPHOS) become downregulated (1). In LPS-activated macrophages, the Krebs cycle (also known as the citric acid or tricarboxylic acid cycle) and OXPHOS are initially upregulated, followed by the nitric oxide–mediated disruption of the Krebs cycle and respiratory chain (2–7), resulting in the accumulation of immunometabolites such as succinate, fumarate, and itaconate, which exhibit a wide range immunoregulatory functions (8–11). In 2011, itaconate was shown to be a mammalian metabolite produced in large quantities in LPS-activated macrophages (12) and present in the lungs of mice infected with Mycobacterium tuberculosis (13). Michelucci et al. then identified cis-aconitate decarboxylase (ACOD1), encoded by immunoresponsive gene 1 (Irg1), as the enzyme responsible for the decarboxylation of the Krebs cycle intermediate cis-aconitate in macrophages (14). ACOD1 had been identified as an LPS-inducible cDNA with no known function in 1995 (15). To date, macrophages and myeloid cells are the only cells that have been found to produce itaconate in response to M1-polarizing conditions (e.g., LPS exposure). Since its identification, itaconate has emerged as a mitochondrial metabolite with antimicrobial but also immunomodulatory properties. In this Review, we discuss these properties and speculate on the therapeutic potential of itaconate in inflammatory diseases. Structurally, itaconate is a five-carbon dicarboxylic acid with an α,β-unsaturated alkene (Figure 1 and ref. 16). It is structurally and chemically similar to other metabolites such as phosphoenolpyruvate, succinate, malonate, and fumarate. Such similarities have informed studies of its antimicrobial and immunoregulatory effects. Esterified derivatives of itaconate, 4-octyl itaconate (OI) and dimethyl itaconate (DI) (Figure 1), are commonly used to mimic its biological effects in vitro and in vivo because of their high membrane permeability, as it was unclear until recently whether underivatized itaconate is able to be taken up by macrophages (17). However, increased electrophilicity of derivatives, or other chemical differences, may reveal effects that are not attributable to endogenously produced itaconate. The use of derivatives is an important area for the field and will be discussed in more detail; it may point the way to novel therapeutics based on itaconate. [Figure: The structures of itaconate, similar metabolites, and its derivatives.Itaconate is a five-carbon dicarboxylic acid with an α,β-unsaturated alkene, making it mildly electrophilic. Structurally, itaconate is similar to several metabolites, including succinate, malonate, phosphoenolpyruvate, and fumarate. For instance, through structural similarity to succinate and malonate, itaconate can competitively inhibit succinate dehydrogenase and prevent the oxidation of succinate to fumarate (53, 54). Similarly, the alkene group allows itaconate to act as a Michael acceptor and react with cysteine residues in a similar manner to fumarate (11). Commonly used derivatives of itaconate include 4-octyl itaconate (OI) and dimethyl itaconate (DI), which are useful because of their high membrane permeability. While DI is not metabolized to itaconate (109), there is evidence that OI may be converted into itaconate intracellularly by esterases (11, 77, 78).] ROLES FOR ITACONATE IN HOST-PATHOGEN INTERACTIONS Since the identification of itaconate as a mammalian metabolite, many studies have characterized roles for itaconate in host-pathogen interactions (Figure 2). Key inducers of the IRG1/itaconate axis in myeloid cells, such as exposure to LPS and acute iron deprivation, occur during infection, indicating an important role for itaconate in infection (18). A notable antimicrobial mechanism of itaconate is its activity as a bacterial isocitrate lyase (ICL) inhibitor (19–21). ICL is a bacterial enzyme required for the glyoxylate shunt during bacterial infection (22–25). As such, inhibition of ICL by itaconate limits growth of pathogens that depend on ICL activity such as Pseudomonas indigofera (19, 21, 26, 27). Recently, a breakdown product of itaconate metabolism, itaconyl-CoA, was also shown to limit the growth of M. tuberculosis (28). During M. tuberculosis infection, cholesterol-derived propionyl-CoA metabolism is required for optimal pathogenicity (29). Itaconyl-CoA, which had previously been shown to inhibit human 5-deoxyadenosylcobalaman-dependent methylmalonyl-CoA mutase (hMCM; ref. 30), was also found to inhibit propionate-dependent M. tuberculosis growth (28), which requires MCM activity (31). Additionally, itaconate prevents M. tuberculosis–associated immunopathology by reducing macrophage chemokine production and inhibiting neutrophil recruitment to the lungs of M. tuberculosis–infected mice (32). [Figure: The effect of itaconate on bacteria and viruses.Upon exposure to pathogens, Irg1 is induced, mediating the production of Krebs cycle–derived itaconate within mitochondria (7). In neurons, Irg1 is induced through ZBP1, RIPK1/3, and IRF1 to restrict Zika viral replication through inhibition of SDH (49). Itaconate is also produced to inhibit the growth of bacteria such as Mycobacterium tuberculosis and Salmonella (28, 33). A notable antimicrobial mechanism is the inhibition of bacterial isocitrate lyase (ICL), which blocks the glyoxylate shunt that is required for optimal growth and pathogenicity (19, 21). The breakdown product of itaconate, itaconyl-CoA, is also an inhibitor of methylmalonyl-CoA mutase (MCM) in bacteria (e.g., M. tuberculosis), thereby blocking propionyl-CoA–dependent bacterial growth (28). Recently, itaconate was shown to be delivered to Salmonella-containing vacuoles, which limits bacterial growth. Mechanistically, this was found to occur through the Rab32 GTPase and its exchange factor, BLOC3, which interact with ACOD1 to target itaconate to bacteria contained within vacuoles (33). Although itaconate is antimicrobial, some pathogens, such as Pseudomonas aeruginosa and Staphylococcus aureus, have developed ways to exploit itaconate to fuel biofilm formation (43, 47). Itaconate causes membrane stress of P. aeruginosa and inhibits aldolase (and glycolysis) in S. aureus, both of which lead to the production of extracellular polysaccharides (EPSs), which further induce Irg1 expression and itaconate synthesis in a positive-feedback manner. EPSs also facilitate the formation of bacterial biofilms, promoting growth and survival of P. aeruginosa and S.

Read the complete text